Biocon Secures 10-Year Pertuzumab Supply Contract in Brazil
Biocon Limited has announced a significant international business development following the signing of a partnership agreement with Bahiafarma and Bionovis for Pertuzumab in Brazil. The agreement covers production and commercialisation of the therapy for HER2-positive breast cancer under Brazil’s Productive Development Partnership (PDP) program.
The company disclosed the development to the Indian stock exchanges on September 8, 2026.
Under the agreement, the consortium comprising Biocon, Bahiafarma and Bionovis has received 100% allocation under Brazil’s 10-year PDP program for Pertuzumab.
Biocon Gets 100% Allocation Under Brazil’s PDP Program
The Productive Development Partnership provides the consortium with exclusive access to Brazil’s public healthcare market for the Pertuzumab opportunity.
According to Biocon, Brazil’s public healthcare market accounts for approximately 70% of the country’s demand for Pertuzumab.
The arrangement is also expected to support the long-term adoption of Biocon’s product within Brazil’s public oncology network.
For Biocon, the agreement provides a long-term opportunity to participate in Brazil’s public healthcare system while expanding access to its oncology product.
Biocon to Receive Milestone Payments and Revenue Share
The financial structure of the agreement includes milestone payments and a share of revenues generated from the Brazil PDP opportunity over the 10 years.
However, Biocon has not disclosed the total contract value, expected revenue, milestone amount, or minimum procurement value associated with the agreement.
Therefore, the announcement should not be interpreted as a ₹ or dollar-denominated order win.
The actual financial contribution to Biocon will depend on the implementation and commercialization of the Pertuzumab opportunity under the PDP framework.
Pertuzumab Production to Be Localized in Brazil
An important component of the agreement is the planned phased localization of the product in Brazil over the medium to long term.
Biocon said the PDP framework will support the development of local capabilities for production while helping expand access to the therapy through Brazil’s public healthcare network.
Pertuzumab is a monoclonal antibody used in the treatment of HER2-positive breast cancer.
According to Biocon, Pertuzumab is currently not manufactured locally in Brazil and represents a significant expenditure for the country’s Unified Health System, or SUS.
The localization programme could therefore have significance beyond the commercial opportunity, as it is aligned with Brazil’s efforts to strengthen domestic capabilities for complex biological medicines.
What Biocon Management Said
Shreehas Tambe, CEO & Managing Director, Biocon, said Brazil is an important market for the company and described the long-term Pertuzumab supply contract as a significant milestone.
He highlighted the partnership with Bahiafarma and Bionovis as an opportunity to combine scientific capabilities, manufacturing expertise, and local knowledge to create a more sustainable pathway for access to the cancer therapy in Brazil.
Tambe also emphasized the potential of the partnership to strengthen Brazil’s healthcare ecosystem while expanding patient access to the treatment.
Role of Bahiafarma and Bionovis
Bahiafarma is a public pharmaceutical laboratory of the State of Bahia, Brazil. It focuses on pharmaceutical research, technological development, innovation, and the production and supply of medicines and healthcare products, particularly for Brazil’s SUS.
Bionovis is a Brazilian biotechnology company focused on developing, manufacturing, and commercializing complex biological medicines and biosimilars. Its activities include technology transfer, local biopharmaceutical manufacturing, and expanding access to advanced therapies in Brazil.
The combination of Biocon’s pharmaceutical capabilities with Bahiafarma’s public-sector role and Bionovis’ local biotechnology expertise forms the basis of the Brazil PDP partnership.
Why This Is Important for Biocon
The 10-year Pertuzumab agreement strengthens Biocon’s international presence in the oncology and biosimilars market and provides a long-term route into Brazil’s public healthcare system.
The 100% allocation under the PDP programme is particularly important because the consortium will have exclusive access to the relevant public healthcare opportunity.
The agreement also provides Biocon with potential revenue visibility through milestone payments and revenue sharing over the 10 years.
At the same time, the company is pursuing an asset localization strategy in Brazil, which could strengthen its long-term position in the country’s biological medicines market.
Investor Takeaway
For investors tracking Biocon Limited, the Brazil Pertuzumab agreement is a strategically important international development.
The key positives are the 10-year PDP framework, 100% allocation, exclusive access to Brazil’s public healthcare market, potential milestone payments, revenue sharing, and planned local production.
However, investors should note that Biocon has not disclosed the overall financial value of the agreement. Consequently, the announcement should be viewed primarily as a long-term strategic and commercial opportunity rather than as a quantified order win.
The development will be worth monitoring as the PDP programme progresses, particularly with respect to regulatory approvals, localization, production, commercialization and revenue generation.
Biocon Limited: Key Points
- Company: Biocon Limited
- NSE Symbol: BIOCON
- Product: Pertuzumab
- Therapeutic Area: HER2-positive breast cancer
- Brazil Partners: Bahiafarma and Bionovis
- Programme: Productive Development Partnership (PDP)
- Allocation: 100%
- Duration: 10 years
- Public Market: Brazil’s Unified Health System (SUS)
- SUS Share of Pertuzumab Demand: Approximately 70%
- Commercial Structure: Milestone payments plus revenue sharing
- Localization: Phased local production in Brazil
- Contract Value: Not disclosed
Source: Biocon Limited regulatory filing and press release dated September 8, 2026.
Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security.